By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



700 Technology Square, 3rd Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-231-6020 Fax: n/a


Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan takes advantage of recent scientific breakthroughs in rare diseases and leveraging a creative approach to drug development and operates in an externally focused, highly collaborative and capital efficient manner.

The accelerator is targeting programs that can make a significant impact on the lives of patients with rare diseases, focusing on advancements with large clinical benefit.

Cydan focuses on identifying promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data are generated during a rigorous diligence and de-risking process to enable subsequent financing and formation of successful stand-alone companies and strategic partnerships.

Based in Cambridge, Mass., Cydan was founded by a management team with extensive drug development, business development and commercialization experience across the biopharmaceutical, venture capital and consulting industries, and strong relationships with non-profit organizations and research foundations.

Cydan launched in 2013 with $26 million in financing led by New Enterprise Associates (NEA), Pfizer Venture Investments, Lundbeckfond Ventures and Bay City Capital with participation from Alexandria Real Estate Equities, Inc.

Key Statistics

Ownership: Private

Web Site: Cydan
Employees: n/a


Start Up

Company News
Cydan Celebrates Rare Disease Day With Gift To Support The Children's National Rare Disease Institute 2/28/2017 6:28:19 AM
Cydan Announces The Promotion Of James Mcarthur, Ph.D. To President, Research And Development 10/11/2016 11:59:53 AM
Cydan Awards Five Scholarships To Support Innovations Impacting Individuals With Rare Conditions 7/13/2016 10:20:01 AM
Cydan Churns Out Second Rare Disease Biotech Imara with $31 Million 4/14/2016 5:47:02 AM
Cydan Announces The Promotion Of Dione Kobayashi, Ph.D., To Vice President, Preclinical Translation 11/4/2015 11:23:07 AM
Cydan Announces Recipients Of Its MassChallenge Scholarship 6/24/2015 2:55:29 PM
Cydan Supports Innovation For Patients With Rare Diseases Through MassChallenge Scholarships 3/19/2015 10:16:59 AM
Orphan Drug Accelerator Cydan Supports Rare Disease Day® And Joins Patients, Advocates And Massachusetts Legislators To Raise Awareness For Rare Diseases 2/23/2015 11:01:56 AM
Orphan Drug Accelerator Cydan Expands Transactional Expertise With Appointment Of Vered Bisker-Leib, Ph.D., MBA, As Chief Business Officer 10/15/2014 9:14:31 AM
Cydan Expands Initial Financing to $26 Million; Additional Money Validates Unique Orphan Drug Accelerator Model 10/1/2013 6:49:50 AM